Fibroblast growth factor 23 (FGF23) regulates phosphorus metabolism and is a strong predictor of mortality in dialysis patients. FGF23 is thought to be an early biomarker of disordered phosphorus metabolism in the initial stages of chronic kidney disease (CKD). We measured FGF23 in baseline samples from 3879 patients in the Chronic Renal Insufficiency Cohort study, which is a diverse cohort of patients with CKD stage 2-4. Mean serum phosphate and median parathyroid hormone (PTH) levels were in the normal range, but median FGF23 was markedly greater than in healthy populations, and increased significantly with decreasing estimated glomerular filtration rate (eGFR). High levels of FGF23, defined as being above 100 RU/ml, were more common than secondary hyperparathyroidism and hyperphosphatemia in all strata of eGFR. The threshold of eGFR at which the slope of FGF23 increased was significantly higher than the corresponding threshold for PTH based on non-overlapping 95% confidence intervals. Thus, increased FGF23 is a common manifestation of CKD that develops earlier than increased phosphate or PTH. Hence, FGF23 measurements may be a sensitive early biomarker of disordered phosphorus metabolism in patients with CKD and normal serum phosphate levels. Fibroblast growth factor 23 (FGF23) regulates phosphorus and vitamin D metabolism. In healthy individuals, FGF23 is secreted by osteocytes in response to dietary phosphorus loading or an increase in 1,25-dihydroxyvitamin D (1,25D) levels, and it stimulates phosphaturia, and reduces 1,25D and parathyroid hormone (PTH) levels.
1,2 FGF23 achieves its cellular specificity in the kidney and parathyroid glands by binding the co-receptor klotho, which increases the affinity of FGF23 for ubiquitously expressed FGF receptors. 3 In patients with chronic kidney disease (CKD), FGF23 levels are thought to increase as a compensatory response to maintain normal phosphate balance, as the capacity for renal phosphorus excretion declines. [4] [5] [6] Hyperphosphatemia is a risk factor for cardiovascular disease and mortality and thus a potential target for interventions to improve clinical outcomes in CKD. 7 However, serum phosphate levels are normal in the vast majority of patients with early and intermediate stages of CKD due to compensatory increases in FGF23 and PTH. 5, 8 While this limits the use of serum phosphate as an early indicator of disordered phosphorus metabolism, it has been proposed that FGF23 screening could identify which patients with early-stage CKD and normal serum phosphate levels might benefit from intervention. 7 In support of this view, high FGF23 levels are more strongly associated with kidney disease progression, left ventricular hypertrophy, vascular disease, and mortality than serum phosphate levels, and were most predictive of adverse events in patients with normal serum phosphate. [9] [10] [11] [12] [13] Although these results are promising, critical questions about the role of FGF23 in mineral metabolism remain unresolved.
14 For example, whether FGF23 or PTH increases first in patients with CKD is not clear, because previous human studies were limited by small sample size or a narrow distribution of glomerular filtration rate (GFR). [4] [5] [6] As a result, few studies directly compared the prevalence of FGF23 excess versus secondary hyperparathyroidism within fine strata across the spectrum of GFR. Furthermore, no large cohort studies of CKD patients examined the impact of dietary phosphorus intake, race, ethnicity, and socioeconomic status on FGF23 levels. We measured FGF23 in baseline samples from 3879 participants in the prospective Chronic Renal Insufficiency Cohort (CRIC) study. The purpose of our study was to characterize FGF23 levels in this national multicenter, racially and ethnically diverse population of CKD patients not yet on dialysis, to compare the relationships of FGF23 versus PTH with declining GFR, and to describe the relationship between FGF23, dietary phosphorus intake, and other measures of phosphorus metabolism across the spectrum of GFR.
RESULTS

Description of the study population
Characteristics of the 3879 CRIC participants are presented in Table 1 . The mean estimated GFR (eGFR) at the baseline visit was 42.8 ± 13.5 ml/min per 1.73 m 2 and the range was 7.0-114.0 ml/min per 1.73 m 2 ; 10% of patients had CKD stage 2, 70% stage 3, and 19% stage 4. Median estimated daily consumption of phosphorus was 1050 mg (interquartile range (IQR): 745-1417), median 24-h urinary phosphate excretion was 713 mg (IQR: 512-953), and median fractional excretion of phosphate (FEPi) calculated from the 24-h specimens was 25% (IQR: [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] . In the overall population, mean serum phosphate (3.7 ± 0.7 mg/dl), mean serum calcium (9.2 ± 0.5 mg/dl), and median plasma PTH (54; IQR: 35-89 pg/ml) were within the normal range. Among the 333 participants with available measurements, mean 25-hydroxyvitamin D (25D) was 21±11 ng/ml, 41% of patients had insufficient vitamin D levels (15-30 ng/ml), an additional 35% were deficient (o15 ng/ml), and 25D levels correlated inversely with PTH (r ¼ À0.44, Po0.001).
The median FGF23 level was 145 RU/ml (IQR: 96-239), which is markedly higher than levels observed in healthy patients. 15, 16 When stricter criteria for CKD were applied (eGFR o60 ml/min per 1.73 m 2 , age o70 years, and urine albumin/creatinine ratio 430 mg/g), the median FGF23 rose to 175 RU/ml (IQR: 114-289). A total of 72% of participants met the criterion for FGF23 excess, which we defined as X100 RU/ml. This threshold is 2.5-fold higher than the median FGF23, and it is in the 90th percentile of the FGF23 distribution observed in previous studies of populations in which B80% of patients had normal kidney function (eGFR 460 ml/min per 1.73 m 2 ). 15, 16 This threshold has also been associated with CKD progression, cardiovascular disease, and mortality in previous prospective studies of CKD patients. 9, 13 Using an even more conservative threshold of X125 RU/ml to define FGF23 excess, 59% of participants qualified. Consistent with previous reports, 4,5 the strongest univariate correlate of FGF23 was eGFR (r ¼ -0.52, Po0.0001). FGF23 also correlated directly with PTH (r ¼ 0.37, Po0.0001) and serum phosphate (r ¼ 0.35, Po0.0001), and inversely with 1,25D (r ¼ -0.26, Po0.0001), in the 332 participants for whom these levels were available. Each of these associations remained significant after adjusting for eGFR. While there was no significant relationship with 24-h urinary phosphate when adjusted for eGFR, higher FGF23 was linearly associated with FEPi (r ¼ 0.25, Po0.0001). Additional factors associated with a higher FGF23 adjusted for eGFR included younger age, female gender, black race, and lower annual income (Po0.008 for each).
Mineral metabolites in relation to GFR Table 2 presents the interrelationships between mineral metabolites and renal function after dividing the cohort into seven fine strata of descending eGFR. Beginning at an eGFR o60 ml/min per 1.73 m 2 , serum phosphate, PTH, and FGF23 levels increased in each consecutive stratum of descending eGFR. Similarly, the prevalence of hyperphosphatemia (phosphate X4.6 mg/dl), secondary hyperparathyroidism (PTH X65 pg/ml), and FGF23 excess (FGF23 X100 RU/ml) increased progressively with declining eGFR (Figure 1 ). Consistent with previous reports, 8 hyperphosphatemia was a late manifestation of CKD, as the prevalence first exceeded 10% in patients with eGFR o39 ml/min per 1.73 m 2 . In contrast, abnormalities in FGF23 levels were an early finding. At an eGFR of 50-59 ml/min per 1.73 m 2 , 450% of patients had an FGF23 X100 RU/ml when only 3% were hyperphosphatemic and only 22% manifested secondary hyperparathyroidism. Among participants with eGFR X70 ml/min per 1.73 m 2 , 33% had FGF23 levels X100 RU/ml. Given the imprecision of eGFR, especially among individuals with mostly preserved renal function, 17 we reevaluated the above relationships in the subset of participants (N ¼ 1434) who underwent direct GFR measurements with 125-I iothalamate clearance (iGFR). Estimated GFR and iGFR were highly correlated (r ¼ 0.82, Po0.0001), hence the results conveyed in Table 2 and Figure 1 were qualitatively unchanged when analyzed according to iGFR.
Estimated daily dietary phosphorus intake was qualitatively similar across the spectrum of eGFR and did not correlate significantly with FGF23, phosphate, or PTH levels. FEPi increased but total 24-h urinary phosphate excretion decreased with decreasing strata of eGFR (Table 2) . Similarly, the ratio of 24-h urinary phosphate excretion/estimated daily dietary phosphorus intake decreased from 470% in participants with eGFR 439 ml/min per 1.73 m 2 to 53% in those with eGFR o20 ml/min per 1.73 m 2 . This decrease coincided with the gradual increase in serum phosphate levels. 
Relationships of FGF23 and PTH with eGFR
To further compare the relative prevalence of abnormally high FGF23 versus PTH levels across the spectrum of eGFR, we calculated the proportions of participants with normal or high FGF23 and PTH levels within each eGFR category ( Figure 2 ). As expected, the most common pattern in the strata of more preserved eGFR was normal FGF23/normal PTH, whereas high FGF23/high PTH was predominant in the lower eGFR strata. In the intermediate eGFR range of 30-60 ml/min per 1.73 m 2 , an isolated increase in FGF23 was the most common pattern and was far more likely than an isolated increase in PTH, which was the rarest combination in all eGFR categories. For example, among participants with eGFR 30-60 ml/min per 1.73 m 2 and an FGF23 X100 RU/ml, only 40% met criteria for secondary hyperparathyroidism, whereas among those with established secondary hyperparathyroidism, FGF23 was X100 RU/ml in 85% of participants. Indeed, in the overall population, the combination of high FGF23/normal PTH was 6.4-fold more prevalent than normal FGF23/high PTH (Po0.0001). Using a more conservative cut-point of X125 RU/ml to define FGF23 excess did not qualitatively alter the results: the combination of high FGF23/normal PTH remained 2.8-fold more prevalent than normal FGF23/high PTH (Po0.0001). The results were also unchanged when defining secondary hyperparathyroidism based on the 1-84 PTH assay and its upper limit of 36 pg/ml. 18 Excluding participants treated with phosphate binders, active vitamin D, or vitamin D supplements did not alter these findings. The relationships between eGFR and mineral metabolites did not vary by sex or race.
Finally, we plotted FGF23 and PTH versus eGFR expressed on a continuous scale using cubic splines, and estimated the eGFR threshold at which there was a statistically significant increase in the slope of each hormone. As shown in Figure 3a and b, the slope of the FGF23 curve increased at an eGFR threshold of 57.8 ml/min per 1.73 m 2 (95% confidence interval: 55.4-60.8), which was significantly higher (based on non-overlapping 95% confidence intervals) than the comparable threshold for PTH of 46.9 ml/min per 1.73 m 2 (95% confidence interval: 45.5-51.4). Adjustment for age and fasting status did not change the results. In aggregate, these data suggest that FGF23 increases earlier in the course of CKD than PTH.
Serum and urinary phosphate in relation to eGFR Next, we plotted serum phosphate and urinary FEPi in relation to eGFR using fitted splines and tested whether there were thresholds of eGFR at which there was a statistically significant change in their slopes (Figure 4) . Log FEPi increased uniformly across the spectrum of decreasing eGFR without a detectable threshold. In contrast, serum phosphate demonstrated a J-shaped curve: levels declined (slope ¼ À0.017±0.002) between the upper range of eGFR through an eGFR of 59.1 ml/min per 1.73 m 2 (95% confidence T
interval: 48.6-63.9), whereas below an eGFR of 59.1, serum phosphate increased (slope ¼ þ 0.067 ± 0.003). The results remained unchanged following adjustment for age and fasting status. These data are consistent with the subtle decrease in serum phosphate levels in the stratum with eGFR of 60-69 ml/min per 1.73 m 2 compared with the adjacent higher and lower strata (Table 2) . Furthermore, when juxtaposed with data in Table 2 , these results suggest two phases in the serum phosphate curve (Figure 4 ). In the proposed first phase (eGFR 459.1 ml/min per 1.73 m 2 ), the subtle reduction in serum phosphate levels was observed in association with increased FGF23 and FEPi, and decreased 1,25D levels. In the proposed second phase (eGFR o59.1 ml/min per 1.73 m 2 ), serum phosphate levels gradually increased from their nadir whereas FGF23 increased more sharply, FEPi continued to increase, and 1,25D decreased further.
DISCUSSION
In this study of nearly 4000 CKD patients, the largest human study of FGF23 to date, we validate that FGF23 is elevated in CKD patients, increases as eGFR falls, and both FGF23 and PTH increase before hyperphosphatemia first appears. [4] [5] [6] Despite being limited by its cross-sectional design and incomplete vitamin D data, our study suggests that FGF23 excess may be the earliest bellwether of disordered mineral metabolism in CKD.
Although levels of FGF23 and PTH are each markedly increased in advanced renal failure, 5, 8 the results of this study suggest that the increase in FGF23 precedes that of PTH. As expected, both FGF23 and PTH were elevated in most patients with extremely low eGFR, and many patients with the most preserved eGFR had normal levels of each. However, an increased FGF23 in the setting of a normal PTH was 46 times more likely than an isolated increase in PTH. Furthermore, the slope of FGF23 versus eGFR turned upwards at a significantly higher eGFR than the comparable threshold for PTH. Importantly, vitamin D deficiency, which is known to raise PTH, was present in 76% of participants and was inversely correlated with PTH. The finding that PTH rises after FGF23 despite the high frequency of vitamin D deficiency further supports the temporal sequence we propose. Nonetheless, 5.8% of participants had isolated PTH elevations, suggesting that additional FGF23-independent factors drive an initial increase in PTH in certain CKD patients.
Although the weight of evidence favors FGF23 elevation as the upstream pathophysiological event that lowers 1,25D and thus increases PTH, as was recently shown in elegant experiments using an animal model of CKD and anti-FGF23 antibodies, 19 the primary stimulus for enhanced FGF23 secretion in early CKD is less clear. On the basis of scant human and experimental data, it has been proposed that decreased expression of klotho may be one step further upstream from FGF23 excess. 20 Indeed, parathyroid resistance to the inhibitory effects of FGF23 is mediated, in part, by downregulation of klotho. [21] [22] [23] However, if klotho deficiency is the primary factor that causes renal resistance to FGF23 and drives secondary, appropriate increases in FGF23 secretion, CKD patients should manifest at least subtle signs of klotho deficiency early in the course of their disease: modest increases in serum phosphate, 1,25D and calcium levels. On the contrary, increases in 1,25D and serum calcium are not observed in early CKD, and we and others observed a modest reduction in serum phosphate during early CKD. 24, 25 This decrement was accompanied by elevated FGF23 and FEPi and lower 1,25D levels, a constellation of metabolic changes that characterize syndromes of primary FGF23 excess, such as X-linked hypophosphatemia, 26 but not syndromes of primary klotho deficiency. 27 An alternative, unifying explanation is that the initial increase in FGF23 in early CKD causes secondary downregulation of klotho, perhaps in response to relative hypophosphatemia or reduced 1,25D, which is known to regulate klotho expression. 28 Indeed, in transgenic mice engineered to overproduce FGF23, klotho was the most significantly inhibited transcript. 29 Although we were not able to measure klotho levels, the pattern of metabolic changes that we observed suggests that increased FGF23 precedes klotho deficiency.
It has also been postulated that FGF23 increases in CKD as an appropriate response to minimize 'phosphate retention', but our data suggest other possible factors. The early reduction in serum phosphate levels in association with already elevated FGF23 levels (proposed phase 1) suggests that perhaps renal injury itself may be an initial stimulus for FGF23 secretion in early CKD by causing increased production of a factor that stimulates FGF23 secretion or decreased expression of a tonic inhibitor. Animal studies in which FGF23 rose immediately after the kidney was injured but before any increase in serum phosphate support this possibility, 19 as do human data that reported an upwards inflection in FGF23 levels as early as an eGFR of 90 ml/min per 1.73 m 2 , 30 and our finding that 33% of participants with an eGFR X70 ml/min per 1.73 m 2 had FGF23 levels X100 RU/ml. Furthermore, patients with autosomal dominant polycystic kidney disease and preserved eGFR exhibited elevated FGF23 levels and subtly reduced serum phosphate levels, 31 which is consistent with our results. Below an eGFR of 60 ml/min per 1.73 m 2 , serum phosphate rose gradually (proposed phase 2) concurrent with a decrease in the ratio of 24-h phosphate excretion/ estimated daily phosphorus intake. Though we only had data from a single 24-h urine collection and dietary assessment, and we did not have 1,25D measurements in the entire cohort, several possibilities may explain this finding. First, serum phosphate could have risen with declining eGFR as a simple adaptation to increase the filtered load of phosphate to overcome the partially reduced capacity for urinary excretion, as has been previously described. 32 This construct implies the maintenance of even phosphate balance at the cost of a modest increase in serum levels. Second, the eGFRdependent, progressive reduction in the ratio of phosphorus excretion/intake could reflect a gradual reduction in the percent of ingested phosphorus that was absorbed, as has been reported previously. [33] [34] [35] This would also imply even phosphate balance and could occur through direct FGF23-dependent inhibition of sodium-phosphate transporters in the gut, 36 FGF23-mediated reductions in 1,25D levels that decrease vitamin D-dependent phosphorus absorption, or reduced vitamin D-dependent calcium absorption that leads to an increase in luminal calcium that acts as an endogenous phosphate binder to limit absorption. 37 Third, if the percent of dietary phosphorus intake that was absorbed remained constant as eGFR declined, then the lower 24-h excretion would signify positive phosphate balance that was reflected in the modest increase in serum phosphate. This paradigm would entail progressive total body phosphate overload, beginning in late stage 3-4, as has been commonly assumed but contradicted by classic balance studies. 38, 39 Deciphering these possibilities will require detailed balance studies across a range of eGFR.
Not all of the CKD patients had elevated FGF23 levels, and there was significant variability across the spectrum of eGFR. Some of this heterogeneity may be because of unknown physiological or genetic factors, 40 but our finding that lower income was associated with higher FGF23 independent of eGFR suggests important environmental factors. We previously reported that poverty was independently associated with higher serum phosphate levels in CKD and non-CKD patients, and speculated that this may be because of impoverished individuals disproportionately consuming excessive amounts of cheap, processed foods laden with highly bioavailable phosphorus-rich additives. 41, 42 The independent association between poverty and increased FGF23 supports this hypothesis. On the basis of these data and the published literature, we propose that the heterogeneous distribution of FGF23 levels across CKD patients likely results from a combination of fixed genetic determinants, the severity of kidney disease, and modifiable components, such as dietary phosphorus intake.
The recent observation that even small increments in serum phosphate are independently associated with adverse renal and cardiovascular events 43, 44 has sparked intense interest in initiating treatment of disordered phosphorus metabolism earlier in the course of CKD. While additional work is needed to establish physiologically based normal ranges of FGF23 and threshold levels that predict clinically meaningful outcomes, FGF23 has the potential to be a novel, easily measurable biomarker to help guide the efficient design of randomized controlled trials to determine whether early initiation of therapy with phosphate binders and dietary phosphorus restriction will improve clinical outcomes in CKD. 7 In support of this approach, previous data demonstrated that FGF23 is a powerful prognostic predictor of adverse clinical outcomes in CKD [9] [10] [11] [12] [13] and that dietary phosphate binders can lower FGF23 in this population. 45 The current study offers additional important insight into the design of a clinical outcomes trial targeting phosphorus metabolism in early CKD. On the basis of the results of this study, we propose that patients with the triad of eGFR o60 ml/min per 1.73 m 2 , FGF23 X100 RU/ml, and serum phosphate X3.5 mg/dl would be ideal candidates Kidney International (2011) 79, 1370-1378 most likely to benefit from interventions targeting phosphorus metabolism.
MATERIALS AND METHODS
Description of cohort CRIC is a multicenter prospective cohort study of risk factors for cardiovascular disease and progression of CKD. 46 Additional Hispanic participants were enrolled in the ancillary Hispanic CRIC study to distinguish CRIC as the largest, most racially and ethnically diverse CKD cohort available to date. Adult patients aged 21-74 years with mild to moderate CKD, defined as an age-stratified eGFR at the screening visit between 20-70 ml/min per 1.73 m 2 , were enrolled. Individuals who were eligible based on their screening eGFR but whose eGFR at the first study visit was found to be outside the range of 20-70 ml/min per 1.73 m 2 were retained in the study. Patients were excluded for pregnancy, New York Heart Association class III-IV heart failure, HIV, cirrhosis, myeloma, renal cancer, recent chemotherapy or immunosuppressive therapy, polycystic kidney disease, organ transplantation, or previous treatment with dialysis for 41 month. The CRIC protocol was approved by the institutional review boards at each of the seven primary sites. All participants provided written informed consent.
Study population
We evaluated 3879 of the 3939 total CRIC and Hispanic CRIC participants who had baseline plasma FGF23 measurements. The mean eGFR of the 60 participants for whom FGF23 measurements were not available did not differ significantly from levels of those included in this analysis (45.0±13.5 versus 42.8±13.5 ml/min per 1.73 m 2 ). Dietary data were available for 2797 participants. The remainder either did not complete the food frequency questionnaire or their data were excluded by the CRIC data-coordinating center because of implausible values for total energy intake. The 24-h urinary data were available for 3659 participants. Serum 25D and 1,25D levels were available in a subset of 333 and 332 participants, respectively. A subset of 1434 participants had GFR measured directly using 125 -I iothalamate clearance (iGFR).
Data collection and measurements
We analyzed the following data that were collected at the baseline visit: demographics, medical history, use of phosphate binders, vitamin D supplements and active vitamin D analogs, blood pressure, anthropometry, fasting blood samples, 24-h urine specimens, and estimated dietary phosphorus, calcium, and caloric intake from the National Cancer Institute's Diet History Questionnaire. 47 Annual household income was self-reported and categorized as o$20,000 per year, $20,001 to $50,000 per year, or 4$50,000 per year.
Comprehensive metabolic panels and urinary biochemical panels were measured using standard assays. In addition to total 24-h urinary phosphate excretion (mg/day), we analyzed urinary FEPi ((urine phosphate Â serum creatinine)/(serum phosphate Â urine creatinine) Â 100%). The latter corrects for over-or undercollections of 24-h urine samples and standardizes urinary phosphate excretion to the degree of renal dysfunction, which is important in CKD cohorts. Plasma FGF23 was measured using the second generation C-terminal assay that detects two epitopes in the C-terminus of FGF23 (Immutopics, San Clemente, CA; coefficient of variation o5%). C-terminal and intact FGF23 assays are highly correlated in CKD, 10 and a recent report of peritoneal dialysis patients that used an in vitro reporter assay suggested that virtually all circulating FGF23 was intact, biologically active, and accurately measured by either assay. 48 Plasma PTH was measured using a total PTH assay, which includes the 1-84 PTH molecule and 7-84 fragments (Scantibodies, Santee, CA; coefficient of variation o5%).
Results from the 1-84 PTH assay were used in secondary analyses. Serum 25D was quantified by radioimmunoassay (Diasorin, Stillwater, MN; coefficient of variation o3%) and serum 1,25D was measured by competitive chemiluminescent immunoassay (Heartland Assays, Ames, IA; coefficient of variation o12%).
Statistical analysis
We evaluated the univariate and eGFR-adjusted correlations between FGF23 and other mineral metabolites using Spearman correlation and linear regression. We performed descriptive analyses of mineral metabolites in the overall population and after categorizing participants into seven fine categories of eGFR (o20, 20-29, 30-39, 40-49, 50-59, 60-69, X70 ml/min per 1.73 m 2 ). We compared mean (median) values within each group to that in the eGFR 470 ml/min per 1.73 m 2 stratum with the use of t-tests or Wilcoxon tests, as appropriate. We defined hyperphosphatemia as serum phosphate X4.6 mg/dl, 8 secondary hyperparathyroidism as PTH X65 pg/ml, 8 and FGF23 excess as FGF23 X100 RU/ml. Because normal reference values for FGF23 in healthy subjects with sufficient vitamin D levels are not available, we used the FGF23 threshold that was 2.5-fold higher than the median FGF23 and in the 90th percentile of the FGF23 distribution in previous studies of populations in which B80% of patients had normal kidney function (eGFR 460 ml/min per 1.73 m 2 ). 15, 16 We estimated the prevalence of abnormally high values of FGF23, PTH, and serum phosphate, and calculated the proportions of participants with either isolated increases in FGF23 or PTH, abnormally high values of both hormones, or normal values of both within each of the seven eGFR categories. We calculated the probability of an elevated FGF23 when PTH levels were o65 pg/ml and, conversely, the probability of an elevated PTH when FGF23 levels were o100 RU/ml. We compared proportions using w 2 -tests. In additional sensitivity analyses, we repeated the probability calculations while excluding individuals treated with vitamin D supplements, phosphate binders, and active vitamin D, after substituting FGF23 X125 RU/ml as the FGF23 cut-point, and PTH 436 pg/ml as the cut-point for the 1-84 PTH assay. 18 We also repeated the main analyses in the subcohort of participants with iGFR.
We used cubic spline regression to fit separate curves for the relationships of log-transformed FGF23 and PTH, with eGFR as the independent variable, and used a bootstrapping procedure to determine the eGFR thresholds at which the slope of FGF23 and PTH became steeper, as described elsewhere. 49 We estimated the value for this threshold as the minimizer of the profile residual sum of squares, as has been done previously. 50 To explore the relationship of serum phosphate and FEPi with eGFR, we used similar methods to test for and estimate the threshold of eGFR at which serum phosphate and FEPi change. Because the fitted spline for serum phosphate displayed a J-shaped pattern, we tested whether there was an eGFR threshold at which the direction of the slope changed. Because eGFR criteria for inclusion were age-stratified, and fasting status can affect levels of mineral metabolites, we performed additional sensitivity analyses that adjusted the spline models for age and fasting status. P-values o0.05 were considered statistically significant. We performed analyses using SAS, version 9.2 (SAS Institute, Cary, NC) and R, Version 2.11.1 (R Foundation for Statistical Computing, Vienna, Austria).
